NCT00775671

Comparative Effect of Nebivolol vs. Metoprolol on Insulin Sensitivity and Fibrinolytic Balance in Metabolic Syndrome

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 46 (actual)
• Sponsor: Vanderbilt University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

Test the hypothesis that nebivolol treatment improves fibrinolytic balance and insulin sensitivity compared to metoprolol treatment in individuals with metabolic syndrome.

Detailed description

1. Test the hypothesis that nebivolol treatment decreases PAI-1 antigen and activity and improves fibrinolytic balance compared to metoprolol treatment in individuals with metabolic syndrome. 2. Test the hypothesis that nebivolol treatment improves insulin sensitivity compared to metoprolol treatment in individuals with metabolic syndrome.

Conditions

• Metabolic Syndrome

Interventions

Type	Name	Description
DRUG	placebo	Placebo pill by mouth daily for 21 days followed by either Nebivolol 5 mg by mouth daily or metoprolol ER 100mg by mouth daily for 12 weeks.
DRUG	Nebivolol	Nebivolol 5 mg by mouth daily for 12 weeks.
DRUG	Metoprolol	Metoprolol ER 100mg by mouth daily for 12 weeks.

Timeline

• Start date: 2008-10-01
• Primary completion: 2011-06-01
• Completion: 2011-06-01
• First posted: 2008-10-20
• Last updated: 2012-10-23
• Results posted: 2012-10-23

Locations

1 site across 1 country: United States